A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

March 23, 2018

Primary Completion Date

March 5, 2020

Study Completion Date

March 5, 2020

Conditions
Type 1 Diabetes
Interventions
DRUG

LY2963016

Administered SC

DRUG

Lantus®

Administered SC

DRUG

Insulin Lispro

Administered SC

Trial Locations (20)

88798

Peking Union Medical College Hospital, Beijing

100044

Peking University Peoples Hospital, Beijing

116023

Dalian Med. Univ. No 2 Affiliate Hospital, Dalian

130041

No.2 Hospital Affiliated to Jilin University, Changchun

200062

Shanghai Putuo District Center Hospital, Shanghai

200072

Shanghai Tenth People's Hospital, Shanghai

210011

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

210012

Nanjing First Hospital, Nanjing

210029

The First Affiliated Hospital with Nanjing Medical Universit, Nanjing

212001

Affiliated Hospital of Jiangsu University, Zhenjiang

213003

Changzhou No.2 People's Hospital, Changzhou

410011

The Second Xiangya Hospital of Central South University, Changsha

430030

Wu Han Tongji Hospital, Wuhan

471003

The 1st Affiliated Hospital of Henan Science and technology, Luoyang

510080

Guangdong Province People's Hospital, Guangzhou

The First Affiliated Hospital, Sun-Yat Sen University, Guangzhou

510120

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou

515041

Shantou University Medical College No.2 Affiliated Hospital, Shantou

610041

West China Hospital of Sichuan University, Chengdu

650034

First People's Hospital of Yunnan Province, Kunming

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03338023 - A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter